> >Register Now <<

Speaker: Jonathan Downar, MD, PhD, FRCPC

Improving access to TMS is a priority for practitioners and patients alike. Multi-day treatment protocols pose a significant logistical barrier to access for many patients, especially those in remote areas.

Recently, proof-of-concept studies have begun to investigate the effectiveness of single-day TMS regimens. Here we review the development of single-day TMS protocols, along with relevant studies on potential mechanisms. We consider new data on the outcomes of single-day TMS in various applications. We examine possible refinements of the approach to improve practicality, tolerability, and effectiveness. We consider important outstanding questions requiring future research on this novel but potentially quite impactful approach to TMS treatment.

Key learning objectives include:

• Review rationale, mechanisms, and history of development of single-day TMS protocols.
• Review recent progress in refining single-day TMS protocols and comparative outcomes vs. conventional once-daily protocols.
• Review outstanding questions facing future developments and refinement of single-day TMS protocols.

Take advantage of our live Q&A session at the conclusion of the webinar.

*Registered attendees will receive access to the on-demand video recording by Friday, January 9, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.

When:

USA - January 6, 2026 at 8:00pm ET | 5:00pm PT
UK- January 7, 2026 at 1:00am GMT
Australia- January 7, 2026 at 12:00pm AEDT

Cost:

Member: $25
Trainee Member: FREE
Non-Member: $50

> >Register Now <<

About the Speaker

Jonathan Downar, MD, PhD, FRCPC

Dr Jonathan Downar is an Adjunct Professor in the Department of Psychiatry and Institute of Medical Science at the University of Toronto. He holds a clinical appointment at the Centre for Addiction and Mental Health in Toronto. He holds a PhD in functional neuroimaging from the University of Toronto, trained in medicine at the University of Calgary, and completed his psychiatry residency at the University of Toronto.

Dr Downar has published over 180 peer-reviewed articles on TMS and brain imaging, in journals including Lancet, JAMA Psychiatry, Nature Medicine, Nature Neuroscience, and Brain Stimulation. He is the senior author of the THREE-D study, a major Canadian TMS study published in Lancet in 2018 that demonstrated that TMS treatments could be reduced from 38 min sessions to 3 minute sessions with no loss of efficacy. He has also pioneered the use of novel TMS protocols including dorsomedial TMS and orbitofrontal TMS in depression and in other clinical disorders.

He is currently working to develop novel protocols that improve the practicality and economics of TMS, with the goal of achieving cost parity with pharmacotherapy and universal access to this powerful treatment.